Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.
Finasteride may help users look younger by suppressing DHT, affecting skin and hair. Users also emphasize skincare, sunscreen, and lifestyle for maintaining a youthful appearance.
The user stopped oral treatments due to side effects and switched to a regimen of topical minoxidil, tretinoin, azelaic acid, and dermaneedling, with recent addition of topical finasteride. They are questioning the long-term effectiveness of non-hormonal methods and considering hair transplantation.
The conversation is about someone's experience with hair loss and their progress using dutasteride, a treatment for hair loss. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
The user is applying topical finasteride with stemoxydine for hair loss and has noticed hair thickening but no regrowth after two months. They also report high SHBG and prolactin levels and a lack of morning erections, even on low doses of medication.
Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.
The Phase 2 trial for Pyrilutamide in the US, which started a year after the China trials, and inquiring about any available information on when it will finish. Treatments discussed include Minoxidil, Finasteride, and RU58841.
The conversation discusses hair loss treatments, focusing on a new slow-release oral minoxidil compared to topical minoxidil and finasteride. The results show that twice-daily dosing of the new treatment is slightly more effective than once-daily, but concerns about cost, side effects, and the accuracy of reported results remain.
The conversation is a humorous take on someone's reaction after their first dose of finasteride for hair loss. Specific treatments mentioned include scalp massage and a protocol of manifestation twice daily.
The conversation discusses being overwhelmed by the variety of hair loss treatments, including finasteride, minoxidil, ketoconazole shampoo, caffeine shampoo, and other supplements like biotin and saw palmetto. The user expresses uncertainty about which treatments to use.
Hair loss treatments, specifically the use of Finasteride, Nizoral, and dermarolling; potential results from these treatments are discussed, along with potential side effects.
The user plans to use RU58841 in the morning and Pyrilutamide in the evening for hair loss treatment, considering replacing Fluridil with Pyrilutamide. They believe Pyrilutamide is effective.
The user discusses their hair loss experience, exploring various hypotheses including thyroid levels, vitamin D, DHEA, nutritional deficiency, diabetes, seborrheic dermatitis, lack of nutrition to hair follicles, chronic inflammation, female pattern hair loss causes, cortisol, and prolactin levels. They are currently using finasteride, beta-sitosterol, and have tried topical dutasteride and microneedling therapy.
A 22-year-old is using a hair loss treatment protocol including dutasteride, microneedling, 10% minoxidil, 0.1% finasteride topical, a healthy diet, and a hair multivitamin. Users discuss the effectiveness of microneedling and the intensity of the treatment.
Finasteride may affect liver function and cortisol levels, potentially linking it to non-alcoholic fatty liver disease (NAFLD). More research is needed to understand this connection fully.
A 26-year-old male is using a combination of clomiphene, minoxidil, tadalafil, bupropion, and lisdexamfetamine to address low testosterone, ED, depression, and focus issues. He seeks input on the safety and efficacy of this regimen, which also includes magnesium, zinc, and fish oil supplements.
Melatonin is being considered as a potential treatment for androgenic alopecia, with some users discussing its effects and combining it with other treatments like minoxidil and finasteride. Concerns about melatonin's impact on hormones and side effects from other treatments like ketoconazole were also discussed.
The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.
Hair loss can cause psychological distress, but maintaining optimism and self-improvement is crucial. Treatments like minoxidil, finasteride, and potential new options like clascoterone offer hope, though side effects can occur.
Finasteride and Dutasteride can be obtained cheaply through Amazon One Medical with an Rx Pass subscription for $20/year. Users discuss various options and costs for hair loss treatments, including Blink Health and Mark Cuban's pharmacy.
New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.
The conversation discusses using topical melatonin for diffuse thinning and mentions treatments like Minoxidil, finasteride, and RU58841. The user is seeking advice on whether melatonin could help with their condition.
The user has been using finasteride and minoxidil for 7 months, seeing thicker hair but no temple regrowth, and is considering switching to dutasteride. Another person suggested trying microneedling on the temples before changing medications.
The user is using a hair loss treatment involving dutasteride, minoxidil, finasteride, microneedling, and supplements like multivitamins, D3 K2, and Omega 3 fish oil. They are considering adding tretinoin and are open to suggestions while managing gut issues.
Dr. Toyos is recruiting more participants for a larger trial on hair loss treatments. The discussion mentions Minoxidil, finasteride, and RU58841 as potential treatments.
Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.